Genprex Strengthens Scientific Advisory Board with Appointment of Lead Researcher of University of Pittsburgh, George K. Gittes, MD

Inventor of the Company’s licensed diabetes gene therapy technology to provide leadership, strategy for diabetes program

Dr. Gittes was recipient of a $2.59 million grant from the National Institutes of Health (“NIH”) National Institute of Diabetes and Digestive and Kidney Diseases for his groundbreaking gene therapy research

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the addition of George K. Gittes, MD to its Scientific Advisory Board (SAB). Dr. Gittes is the inventor of the Company’s licensed diabetes gene therapy technology that is currently in development, and serves as the Chief of Pediatric Surgery and Surgeon-in-Chief Emeritus at the UPMC Children’s Hospital of Pittsburgh.

In February 2020, Genprex signed an exclusive license agreement with the University of Pittsburgh for Dr. Gittes’ diabetes gene therapy technology. Type 1 and Type 2 diabetes together

Read More